

Masatoshi NODA et al.

Docket No. 010969

REMARKS

The above amendment is believed to place the claims in proper condition for examination.

Early and favorable action is awaited.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

In the event there are any additional fees required, please charge our Deposit Account No. 01-2340.

Respectfully submitted,

ARMSTRONG, WESTERMAN, HATTORI,
McLELAND & NAUGHTON, LLP



Atty. Docket No. 010969
Suite 1000
1725 K Street, N.W.
Washington, D.C. 20006
Tel: (202) 659-2930
DWH/yap

Donald W. Hanson
Reg. No. 27,133

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 4-6 and 9-11 have been amended as follows:

4. (Amended) An ADP-ribosylation inhibitor according to ~~any one of claims 1 through 3~~ claim 1, wherein proanthocyanidin is the one extracted with at least one solvent selected from water, an alcohol, an ester and a ketone.
5. (Amended) An ADP-ribosylation inhibitor according to ~~any one of claims 1 through 4~~ claim 1, wherein proanthocyanidin is the one purified using a styrene type adsorption resin, an anionic exchange resin, an octadecyl-chemically binding type silica gel, an octyl-chemically binding type silica gel, a phenyl-chemically binding type silica gel and a silica gel.
6. (Amended) A composition for the treatment and/or prevention of diphtheria, pertussis, tetanus and opportunistic infection, comprising as an effective ingredient an ADP-ribosylation inhibitor according to ~~any one of claims 1 through 5~~ comprising proanthocyanidin as an effective ingredient.
9. (Amended) A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to claim 7 or 8, wherein said edible plant or edible plant-derived material is an extract from an apple or a grape.

10. (Amended) A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to ~~any one of claims 7 through 9~~ claim 7, wherein proanthocyanidin is the one extracted with at least one solvent selected from water, an alcohol, an ester and a ketone.

11. (Amended) A composition for the treatment and/or prevention of enterotoxin type bacterial infectious disease according to ~~any one of claims 7 through 10~~ claim 7, wherein proanthocyanidin is the one purified using a styrene type adsorption resin, an anionic exchange resin, an octadecyl-chemically binding type silica gel, an octyl-chemically binding type silica gel, a phenyl-chemical type binding silica gel and a silica gel.